atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
March 23 2022 - 6:59AM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that it plans to host a
webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its
financial results for the fourth quarter 2021 and provide a
business update.
To access the webcast, please log in
at https://wsw.com/webcast/cc/atai/1358298. The live and
archived webcast of this call will be available in the “Events”
section of the atai Life Sciences website at ir.atai.life.
About atai Life Sciences
atai was founded in 2018 as a response to the significant unmet
need and lack of innovation in the mental health treatment
landscape. atai is dedicated to acquiring, incubating and
efficiently developing innovative therapeutics to treat depression,
anxiety, addiction, and other mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's mission is to bridge the gap between what the mental
healthcare system currently provides and what patients need. atai
has offices in New York, Boston, San Diego, London and Berlin. For
more information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including without limitation
statements regarding atai’s participation in upcoming conferences
and presentations and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors discussed under the caption “Risk Factors” in atai's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities
and Exchange Commission (“SEC”) on June 21, 2021, as such factors
may be updated from time to time in atai's other filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. atai disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, whether as a result of
new information, future events or otherwise, other than to the
extent required by applicable law.
Contact Information
Investor Contact:Greg WeaverChief Financial OfficerEmail:
greg.weaver@atai.life
Media Contact:Camilla DormerVP, Communications Email:
camilla@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024